Advanced Enzyme Technologies Limited has informed the Exchange about Investor Presentation
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Advanced Enzyme Technologies reported FY25 revenue of ₹6,369 crore, up just 2% year-on-year, with EBITDA falling 5% to ₹1,944 crore and profit after tax declining 5% to ₹1,340 crore. Full-year EBITDA margin stood at 31% and PAT margin at 21%, both down from the previous year. The Q4 quarter was notably weak — revenue grew 6% to ₹1,672 crore but EBITDA plunged 18% to ₹456 crore and PAT fell 11% to ₹267 crore, with margins contracting sharply to 27% (EBITDA) and 16% (PAT). Sequentially, profit dropped 31% from Q3 FY25. The human nutrition segment (64% of sales) shrank 3% for the year, while animal nutrition (+12%), specialized manufacturing (+30%), and industrial bio-processing (+6%) provided some cushion. India and Europe sales declined, partly offset by growth in the Americas and Asia.
The sharp Q4 margin compression and sequential profit drop signal near-term earnings pressure despite modest full-year growth, which could weigh on the stock in the short term. The dependence on human nutrition in a softening domestic and European market remains a concern, though newer segments and international expansion provide medium-term growth optionality.